David Cherney, MD, PhD: Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring and Novo-Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); D.Z.I.C has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GSK and Novo-Nordisk: Speaker/Honoraria (Ongoing)
49 yr. with T2D, hypertension, smoker, remote PCI, presents with minor right MCA stroke with atrial fibrillation, EF 60% with creatinine 279, eGFR 27, uACR 5 mg/mmol & K+ 4.8, A1C 7.5. Rx: Metformin 500 mg BID, Sitagliptin 100 mg daily and apixaban 5 mg bid On Preventing CKD progression, ASCVD events (MI & Stroke) and CHF (HFrEF and HFpEF) a. RAAS Inhibition should be routine? b. Advanced and end-stage CKD i. SGLT2i and GLP-1 RA ii. Atrial fibrillation and stroke prevention-VKA, DOAC or “just ASA”? c. MRA and finerenone
